| 6.44 -0.37 (-5.43%) | 08-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.52 | 1-year : | 9.95 |
| Resists | First : | 7.3 | Second : | 8.52 |
| Pivot price | 6.47 |
|||
| Supports | First : | 5.46 | Second : | 4.32 |
| MAs | MA(5) : | 6.73 |
MA(20) : | 6.18  |
| MA(100) : | 5.42 |
MA(250) : | 6.02 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 62.4 |
D(3) : | 74 |
| RSI | RSI(14): 57.9 |
|||
| 52-week | High : | 8 | Low : | 4.32 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BHC ] has closed above bottom band by 46.7%. Bollinger Bands are 19% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.88 - 6.93 | 6.93 - 6.96 |
| Low: | 6.28 - 6.33 | 6.33 - 6.37 |
| Close: | 6.37 - 6.45 | 6.45 - 6.51 |
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
Sat, 22 Aug 2026
Bausch Health Companies Inc (BHC) News, Articles, Events & Latest Updates - Stocktwits
Fri, 21 Aug 2026
What is Zacks Research's Estimate for TSE:BHC Q3 Earnings? - MarketBeat
Thu, 20 Aug 2026
Bausch Health Companies Insider Sold Shares Worth $258,894, According to a Recent SEC Filing - marketscreener.com
Thu, 20 Aug 2026
Bausch Health (BHC) insider sells 36,827 shares in plan trade - Stock Titan
Wed, 19 Aug 2026
Bausch Health (NYSE: BHC) officer may sell stock with vested awards listed - Stock Titan
Tue, 11 Aug 2026
Bausch Health Companies Inc. (BHC) Stock Analysis: Exploring an 18% Upside Amidst Strong Revenue Growth - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 374 (M) |
| Shares Float | 261 (M) |
| Held by Insiders | 11.1 (%) |
| Held by Institutions | 66 (%) |
| Shares Short | 7,370 (K) |
| Shares Short P.Month | 7,440 (K) |
| EPS | -2.95 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.74 |
| Profit Margin | -10.2 % |
| Operating Margin | 27.1 % |
| Return on Assets (ttm) | 6.5 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 12.6 % |
| Gross Profit (p.s.) | 20.82 |
| Sales Per Share | 29.01 |
| EBITDA (p.s.) | 10.45 |
| Qtrly Earnings Growth | 70.4 % |
| Operating Cash Flow | 1,800 (M) |
| Levered Free Cash Flow | 1,430 (M) |
| PE Ratio | -2.2 |
| PEG Ratio | 0 |
| Price to Book value | -1.36 |
| Price to Sales | 0.22 |
| Price to Cash Flow | 1.33 |
| Dividend | 1 |
| Forward Dividend | 0 |
| Dividend Yield | 15.5% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|